Given the global burden of NSCLC and the role of flavonoids in modulating critical oncogenic pathways such as PI3K/Akt, this study aims to investigate isalpinin’s potential as a novel therapeutic agent for NSCLC. The gene discussed is AKT1; the disease is non-small cell lung carcinoma.